Publications scientifiques du Site ANRS Cameroun

Publications de 2016


Evolution of renal function in African patients initiating second line antiretroviral treatment : Findings from the 2LADY-ANRS 12169 trial

Cournil A, Hema A, Eymard-DuvernayS, Ciaffi L, Badiou S, Kabore F, Diouf A, Manga N, Le mo,g V, Reynes J, Koulla Shiro S, Delaporte E

Publications de 2015

1.  HandiVIH. Understanding the vulnerability of people with disabilities to HIV and other sexual and reproductive health problems in Cameroon: protocol and methodological considerations.  De Beaudrap P, Pasquier E, Noelle A, et al.  Open BMJ (en cours de révision, 2015)

2.  Incidence, trends and predictors of infectious morbidity after second line antiretroviral therapy initiation in HIV-infected adults in Yaoundé, Cameroon (submitted CID, 2015).

Publications de 2014

1.     Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Landman R, Koulla-Shiro S, Sow PS, Ngolle M, Diallo MB, Guèye NF, Le Moing V, Eymard-Duvernay S, Benalycherif A, Charpentier C, Peytavin G, Delaporte E, Girard PM; DAYANA Study Group. Antivir Ther. 2014;19(1):51-9. doi: 10.3851/IMP2675.

Publications de 2013

1.   Aghokeng AF, Kouanfack C, Peeters M, Mpoudi-Ngole E, and Delaporte E Successful integrase inhibitor-based HAART for a multidrug-class resistant HIV-1 group O infected patient in Cameroon.
AIDS Res Hum Retroviruses 2013; 29(1):1-3.

Publications de 2012

1.     Vidal N, Diop H, Montavon Cl, Butel C, Bosch Sp, Ngole EM, Tour√©-Kane C, Mboup S, Delaporte E, and Peeters M. A novel Multiregion Hybridization Assay reveals high frequency of dual inter-subtype infections among HIV-positive individuals in Cameroon, West Central Africa.
Infection, Genetics and Evolution (2012); ( ).

Publications de 2011

1.     Laurent C, Tchatchueng Mbougua JB, Ngom Gueye NF, Etard JF, Diouf A, Landman R, Molinari N, Girard PM, Sow PS, Ndoye I, Delaporte E. 
Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal
Trop Med Int Health. (2011);16(2):217-222.